JP2019527563A5 - - Google Patents

Download PDF

Info

Publication number
JP2019527563A5
JP2019527563A5 JP2019526196A JP2019526196A JP2019527563A5 JP 2019527563 A5 JP2019527563 A5 JP 2019527563A5 JP 2019526196 A JP2019526196 A JP 2019526196A JP 2019526196 A JP2019526196 A JP 2019526196A JP 2019527563 A5 JP2019527563 A5 JP 2019527563A5
Authority
JP
Japan
Prior art keywords
mirna
gene construct
modified gene
mir
target cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019526196A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019527563A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/043938 external-priority patent/WO2018022749A1/en
Publication of JP2019527563A publication Critical patent/JP2019527563A/ja
Publication of JP2019527563A5 publication Critical patent/JP2019527563A5/ja
Pending legal-status Critical Current

Links

JP2019526196A 2016-07-26 2017-07-26 時空間調節因子 Pending JP2019527563A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662366755P 2016-07-26 2016-07-26
US62/366,755 2016-07-26
PCT/US2017/043938 WO2018022749A1 (en) 2016-07-26 2017-07-26 Spatiotemporal regulators

Publications (2)

Publication Number Publication Date
JP2019527563A JP2019527563A (ja) 2019-10-03
JP2019527563A5 true JP2019527563A5 (enExample) 2020-09-03

Family

ID=59523304

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019526195A Pending JP2019521717A (ja) 2016-07-26 2017-07-26 遺伝子イレーサー
JP2019526196A Pending JP2019527563A (ja) 2016-07-26 2017-07-26 時空間調節因子

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019526195A Pending JP2019521717A (ja) 2016-07-26 2017-07-26 遺伝子イレーサー

Country Status (8)

Country Link
US (2) US20190169634A1 (enExample)
EP (2) EP3491137A1 (enExample)
JP (2) JP2019521717A (enExample)
KR (2) KR20190053179A (enExample)
CN (2) CN110073000A (enExample)
AU (2) AU2017302589A1 (enExample)
CA (2) CA3031673A1 (enExample)
WO (2) WO2018022749A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3443001B1 (en) 2016-04-11 2025-04-30 Obsidian Therapeutics, Inc. REGULATED BIOCIRCUIT SYSTEMS
EP3235908A1 (en) 2016-04-21 2017-10-25 Ecole Normale Superieure De Lyon Methods for selectively modulating the activity of distinct subtypes of cells
ES3052812T3 (en) 2017-05-08 2026-01-14 Flagship Pioneering Innovations V Inc Compositions for facilitating membrane fusion and uses thereof
MX2020012295A (es) * 2018-05-15 2021-03-31 Flagship Pioneering Innovations V Inc Composiciones de fusosoma y usos de estas.
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
WO2020014209A1 (en) 2018-07-09 2020-01-16 Flagship Pioneering Innovations V, Inc. Fusosome compositions and uses thereof
WO2020086742A1 (en) 2018-10-24 2020-04-30 Obsidian Therapeutics, Inc. Er tunable protein regulation
AU2019378036B2 (en) 2018-11-14 2026-05-07 Flagship Pioneering Innovations V, Inc Compositions and methods for compartment-specific cargo delivery
WO2021100034A1 (en) * 2019-11-19 2021-05-27 Protalix Ltd. Removal of constructs from transformed cells
GB202006462D0 (en) * 2020-05-04 2020-06-17 Mote Res Limited Modifying genomes with integrase
AU2022253020A1 (en) 2021-04-08 2023-10-26 Sana Biotechnology, Inc. Cd8-specific antibody constructs and compositions thereof
EP4731757A2 (en) 2023-06-26 2026-04-29 University of Hawaii Evolved integrases and methods of using the same for genome editing
CN120866333A (zh) * 2024-04-30 2025-10-31 深圳市深研生物科技有限公司 利用膜蛋白进行细胞分选的方法
CN118813656B (zh) * 2024-06-19 2025-06-03 山东大学 一种大片段dna级联组装的方法、系统及应用
GB2642222A (en) * 2024-06-26 2026-01-07 E V A Biosystems Ltd A gene cassette and uses therefor

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19834430C2 (de) * 1998-07-30 2000-05-31 Harald Von Melchner Selbstdeletierende Vektoren für die Krebstherapie
US7189506B1 (en) * 1999-03-03 2007-03-13 Genelabs Technologies, Inc. DNA binding compound-mediated molecular switch system
US20060265771A1 (en) * 2005-05-17 2006-11-23 Lewis David L Monitoring microrna expression and function
ES2564823T3 (es) * 2005-05-27 2016-03-29 Ospedale San Raffaele S.R.L. Vector génico que comprende miARN
EP2377559A1 (en) * 2005-06-03 2011-10-19 Southern Adelaide Health Service - Flinders Medical Centre Targeting cells with altered microRNA expression
US20070054872A1 (en) * 2005-08-24 2007-03-08 Mirus Bio Corporation Regulatable or conditional expression systems
US20080031816A1 (en) * 2006-08-03 2008-02-07 Charles Keller Methods and compositions for identifying biomarkers
US20090286242A1 (en) * 2007-12-10 2009-11-19 Cold Spring Harbor Laboratory MicroRNA Expression Profiling and Uses Thereof
WO2009142602A1 (en) * 2008-05-19 2009-11-26 Agency For Science, Technology And Research Nucleic acid molecule and method of targeting gene expression to gliomas
US20100229254A1 (en) * 2009-03-04 2010-09-09 Kmita Marie Method for targeted cell ablation
US9272053B2 (en) * 2010-04-23 2016-03-01 University Of Massachusetts AAV-based treatment of cholesterol-related disorders
WO2012056440A1 (en) * 2010-10-28 2012-05-03 Nanodoc Ltd. COMPOSITIONS AND METHODS FOR ACTIVATING EXPRESSION BY A SPECIFIC ENDOGENOUS miRNA
CN102719556A (zh) * 2011-03-29 2012-10-10 北京五加和分子医学研究所有限公司 基于AAV载体的高通量miRNA活性检测方法及其应用
WO2012131048A1 (en) * 2011-03-31 2012-10-04 Royal College Of Surgeons In Ireland Treatment and prognosis of solid tumour cancers
CN102358901A (zh) * 2011-11-11 2012-02-22 天津托普泰克生物科技有限公司 Has-miR-520e的抗肿瘤用途
EP2684962A1 (en) * 2012-07-10 2014-01-15 Commissariat A L'energie Atomique Et Aux Energies Alternatives Vector for the selective silencing of a gene in astrocytes
WO2014093852A1 (en) * 2012-12-13 2014-06-19 Massachusetts Institute Of Technology Recombinase-based logic and memory systems
EP2948550A1 (en) * 2013-01-28 2015-12-02 Council of Scientific & Industrial Research METHOD FOR INHIBITING TUMOR GROWTH THROUGH RNA-INTERFERENCE USING LIPOSOMALLY ASSOCIATED CDC20 siRNA
FR3004463A1 (fr) * 2013-04-11 2014-10-17 Genethon Systeme d'expression pour une therapie genique selective
RU2020140209A (ru) * 2014-10-21 2021-01-25 Юниверсити Оф Массачусетс Варианты рекомбинантных aav и их применения
JP2016088884A (ja) * 2014-11-04 2016-05-23 国立大学法人岐阜大学 腫瘍治療用組成物
HK1257177A1 (zh) 2015-06-19 2019-10-18 麻省理工学院 肿瘤免疫治疗
WO2017096363A1 (en) * 2015-12-04 2017-06-08 Board Of Regents, The University Of Texas System Reporter system for detecting and targeting activated cells

Similar Documents

Publication Publication Date Title
Diener et al. Emerging concepts of miRNA therapeutics: from cells to clinic
Brillante et al. Advances in MicroRNA therapeutics: from preclinical to clinical studies
Bernardo et al. miRNA therapeutics: a new class of drugs with potential therapeutic applications in the heart
ES2743188T3 (es) Péptidos y nanopartículas para el suministro intracelular de moléculas
CN106540268B (zh) 一种TDNs-AS1411-核酸药物复合纳米材料载药系统及其制备方法
Giza et al. Key principles of miRNA involvement in human diseases
JP2017509350A5 (enExample)
Andries et al. Synthetic biology devices and circuits for RNA-based ‘smart vaccines’: a propositional review
Kumar et al. Delivery and Targeting of miRNAs for Treating Liver Fibrosis: Kumar and Mahato
Aránega et al. MiRNAs and muscle regeneration: therapeutic targets in Duchenne muscular dystrophy
JP2014527401A5 (enExample)
Pfeifer et al. Harnessing synthetic biology for advancing RNA therapeutics and vaccine design
JP2015513919A5 (enExample)
JP2014518875A5 (enExample)
CN105899663B (zh) 用于基因表达控制的人工模拟miRNA及其用途
Cao et al. Engineering circular RNA medicines
NZ716102A (en) Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues
Zhao et al. microRNAs: critical targets for treating rheumatoid arthritis angiogenesis
Zhang et al. Oligonucleotide‐Based Modulation of Macrophage Polarization: Emerging Strategies in Immunotherapy
Sharma et al. Engineering circular RNA for molecular and metabolic reprogramming
Najmuddin et al. The linkage between microRNA and cancer and its delivery as cancer therapy: a mini-review
kuji Kosuge et al. Identification 0f 0bstructive Jaundice-Related MicroRNAS in Mouse Liver
JP2025049296A (ja) 高度にコンパクトな多入力論理ゲートをコードする核酸ベクターを使用して疾患を処置する方法
Mandal et al. Biogenesis and implication of miRNAs in the development of diseases and their theranostic inhibitions.
CN102206680A (zh) 基于短链核酸片段的基因电转染缓冲液及其制备和应用方法